ClinicalTrials.gg
RecruitingNCT07855679PERSEUSUpdated Oct 15, 2026

Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance

An observational study in Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension and Right Ventricular Dysfunction, sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Azienda Ospedaliero-Universitaria Careggi · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 7, 2026Start date movedEligibility revised+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Venous Thromboembolism with a site in Italy — 10 open to participants now, 13 under way, 3 of them phase 3. Venous Thromboembolism · Italy.

Planned enrollment
10th of 23
5,000 · median 2,040
Started
2026
the only one that year
Observational
23 of 74
7 open now
Primary completion
2031-07
later than 10 of 12 live
Registered
74th of 74
by date

Among the 74 studies in Venous Thromboembolism with a site in Italy, this one is the 10th largest by planned enrollment of the 23 observational ones that give a count, is the only one that started in 2026, is one of 23 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 74th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

10 of the 74 studies in Venous Thromboembolism with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Venous Thromboembolism with a site in Italy, or all of them as a file.
02

Study summary

PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.

Read the detailed description

BACKGROUND AND SCIENTIFIC RATIONALE

Pulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.

STUDY DESIGN AND COHORTS

Time perspective: ambispective (retrospective and prospective cohorts, described below).

PERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:

  1. Retrospective Phase (Historical Cohort): Includes consecutive adult patients diagnosed with acute PE from January 1, 2023, up to the date of local Ethics Committee approval at each participating site. Data are abstracted from medical records.
  2. Prospective Phase (Contemporary Cohort): Enrolls consecutive adult patients presenting with acute PE after local Ethics Committee approval, extending for a continuous enrollment period of 5 years. Data are collected during routine care.

STUDY SETTING AND CLINICAL CONTINUUM OF CARE

Data collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:

  • Baseline Presentation (T0): Captures pre-hospital emergency medical service (EMS) data (initial vital signs, cardiac arrest, point-of-care ultrasound [POCUS], pre-hospital anticoagulation or thrombolysis), ED arrival parameters, clinical symptoms, arterial blood gas analysis, admission laboratory biomarkers (high-sensitivity troponin, BNP/NT-proBNP, lactate, D-dimer, renal function), electrocardiographic patterns, and multiorgan diagnostic imaging (CT pulmonary angiography [CTPA], complete echocardiography/POCUS, and compression venous ultrasound [CUS]).
  • Dynamic In-Hospital Reassessment (T1-T4): To capture real-world hemodynamic and respiratory trajectories, serial parameters documented during standard clinical monitoring are recorded across predefined temporal windows: T1 (3-6 hours), T2 (6-12 hours), T3 (12-24 hours), and T4 (24-48 hours). Parameters include serial vital signs, shock index, respiratory support modalities, serial lactate/troponin kinetics, echocardiographic right ventricular function changes, and need for escalating hemodynamic or respiratory support (vasopressors, inotropes, non-invasive ventilation, mechanical ventilation, or ECMO).
  • Hospital Discharge \& Complications: Documents in-hospital adverse events, need for rescue reperfusion, procedural complications, bleeding events, length of stay, and vital status at discharge.
  • Follow-up Surveillance: Thirty-day status is ascertained from clinical records. Follow-up then reflects routine care at 3 and 12 months and annually thereafter up to 5 years (in-person visit, telemedicine, telephone contact or review of clinical documentation), with regional mortality registries used to ascertain vital status when needed. Follow-up collects all-cause survival, cause of death, VTE recurrence, major and clinically relevant non-major bleeding, persistent functional limitation (modified Rankin Scale, exertional dyspnea, six-minute walk test when performed) and the development of chronic thromboembolic pulmonary hypertension (CTEPH).

OUTCOMES

Outcome definitions and time frames are reported in the Outcome Measures section.

DATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE

Data collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).

  • Privacy and Data Segregation: Strict GDPR compliance is maintained. Patient data are pseudonymized at source by the local site investigator using site-specific Subject IDs. The decoding key linking the alphanumeric ID to personal identifiers is maintained exclusively at the local participating hospital under the responsibility of the local Principal Investigator.
  • Data Access Groups (DAGs): REDCap DAGs are enforced to compartmentalize site-level access, ensuring participating centers can exclusively view, enter, and edit their own center's records, with no unauthorized cross-center data visibility.
  • Quality Assurance: The eCRF includes built-in validation rules (range and logic checks). The coordinating center performs regular central monitoring for inconsistencies, outliers and missing data, and discrepancies are resolved with each center through a formal query process. The Steering Committee reviews enrollment, data quality and protocol adherence every 6 months.
  • Regulatory Framework: Protocol version 2.0 (7 May 2026) received a favourable opinion from the Comitato Etico Regione Toscana - Area Vasta Centro (CEAVC, register no. 30742_oss, meeting of 9 June 2026) for the sites of Azienda Ospedaliero-Universitaria Careggi and Azienda USL Toscana Centro. Participation of other national and international centers is subject to approval of a protocol amendment and of the competent local ethics committees. The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles and applicable privacy regulations (including Article 110-bis of the Italian Privacy Code).
03

Conditions studied

  • Venous Thromboembolism (VTE)
  • Chronic Thromboembolic Pulmonary Hypertension
  • Right Ventricular Dysfunction
  • Pulmonary Embolism (PE)

Keywords

  • Pulmonary Embolism
  • Acute Pulmonary Embolism
  • Venous Thromboembolism
  • Right Ventricular Dysfunction
  • Risk Stratification
  • Prognostic Scores
  • TELOS-plus
  • sPESI
  • Bova Score
  • ESC Guidelines
  • AHA/ACC Guidelines
  • High-Sensitivity Troponin
  • Plasma Lactate
  • Echocardiography
  • CT Pulmonary Angiography
  • Hemodynamic Decompensation
  • Systemic Thrombolysis
  • Catheter-Directed Therapy
  • Observational Registry
  • Real-World Evidence
  • Emergency Department
  • Cardiac Arrest
  • Prehospital Emergency Care
  • Point-of-Care Ultrasound
  • Ambispective Cohort
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older at the time of presentation.
  • Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:
  • Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;
  • Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch;
  • Conventional catheter-directed pulmonary angiography;
  • In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.
  • For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.
  • Written obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.

Exclusion criteria

Exclusion Criteria:

  • Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Adults with acute pulmonary embolism

    Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care).

    Other: Routine clinical care (no study intervention)

Interventions

  • OtherRoutine clinical care (no study intervention)

    Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.

    Also known as: Routine Clinical Practice, Usual Care

06

What researchers measure

Primary outcomes

  1. All-cause mortality at 30 days

    Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries.

    Time frame: 30 days after diagnosis

  2. PE-related mortality at 30 days

    Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought.

    Time frame: 30 days after diagnosis

Secondary outcomes

  1. Hemodynamic decompensation

    Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure \<90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event.

    Time frame: From diagnosis to hospital discharge or day 30, whichever comes first

  2. All-cause mortality during follow-up

    Proportion of patients who die from any cause during follow-up.

    Time frame: 3 months, 12 months, and annually up to 5 years after diagnosis

  3. PE-related mortality during follow-up

    Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome.

    Time frame: 3 months, 12 months, and annually up to 5 years after diagnosis

  4. Recurrent venous thromboembolism

    Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted.

    Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

  5. Major bleeding (ISTH criteria)

    Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening if it is extracranial bleeding causing shock or intracranial hemorrhage with a Glasgow Coma Scale score below 14.

    Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

  6. Clinically relevant non-major bleeding

    Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy.

    Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

  7. Chronic thromboembolic pulmonary hypertension (CTEPH)

    Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure \>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance \>2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC/ERS criteria). Diagnostic tests are performed only when clinically indicated.

    Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

  8. Persistent functional limitation after pulmonary embolism (post-PE syndrome)

    Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care.

    Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

07

Study locations

16 of 16 sites recruiting
  • Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro
    Bagno a Ripoli, Tuscany 50012, Italy
    Recruiting
  • Nuovo Ospedale del Mugello - Azienda USL Toscana Centro
    Borgo San Lorenzo, Tuscany 50032, Italy
    Recruiting
  • Ospedale San Giuseppe - Azienda USL Toscana Centro
    Empoli, Tuscany 50053, Italy
    Recruiting
  • Ospedale Santa Maria Nuova - Azienda USL Toscana Centro
    Florence, Tuscany 50122, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Careggi
    Florence, Tuscany 50134, Italy
    Recruiting
  • Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro
    Florence, Tuscany 50143, Italy
    Recruiting
  • Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro
    Pescia, Tuscany 51017, Italy
    Recruiting
  • Ospedale San Jacopo - Azienda USL Toscana Centro
    Pistoia, Tuscany 51100, Italy
    Recruiting
  • Ospedale Santo Stefano - Azienda USL Toscana Centro
    Prato, Tuscany 59100, Italy
    Recruiting
  • Ospedale Versilia - Azienda USL Toscana Nord Ovest
    Lido di Camaiore, Italy
    Recruiting
  • AORN Antonio Cardarelli
    Naples, 80131, Italy
    Recruiting
  • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
    Perugia, 06129, Italy
    Recruiting
    • Cecilia Becattini, MD, PhD · Contactcecilia.becattini@unipg.it · +390755781
    • Cecilia Becattini, MD, PhD · Principal investigator
  • Azienda Ospedaliero-Universitaria Pisana - Ospedale Cisanello
    Pisa, Italy
    Recruiting
    • Lorenzo Ghiadoni, MD, PhD · Contactlorenzo.ghiadoni@unipi.it · +39050992111
    • Lorenzo Ghiadoni, MD, PhD · Principal investigator
  • AOU Città della Salute e della Scienza di Torino - Presidio Molinette
    Torino, 10126, Italy
    Recruiting
    • Fulvio Morello, MD · Contactfulvio.morello@unito.it · +390116335555
    • Fulvio Morello, MD · Principal investigator
  • Medical University of Warsaw - Infant Jesus Teaching Hospital
    Warsaw, Poland
    Recruiting
    • Piotr Pruszczyk, MD, PhD · Contactpiotr.pruszczyk@wum.edu.pl · +48225021000
    • Piotr Pruszczyk, MD, PhD · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
    Recruiting
    • David Jiménez, MD, PhD · Contactdjimenez.hrc@gmail.com · +34913368000
    • David Jiménez, MD, PhD · Principal investigator
08

References and documents

Publications

  • Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, Ageno W, Cohen AT, Hunt BJ, Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med. 2020 Mar;8(3):277-287. doi: 10.1016/S2213-2600(19)30354-6. Epub 2019 Oct 12. PubMed 31615719 ↗
  • Jimenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M; RIETE Investigators. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. J Am Coll Cardiol. 2016 Jan 19;67(2):162-170. doi: 10.1016/j.jacc.2015.10.060. PubMed 26791063 ↗
  • Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999 Apr 24;353(9162):1386-9. doi: 10.1016/s0140-6736(98)07534-5. PubMed 10227218 ↗
  • Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):370-2. doi: 10.1161/ATVBAHA.108.162545. No abstract available. PubMed 18296591 ↗
  • Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. No abstract available. PubMed 36017548 ↗
  • Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, Manina G, Pomero F, Cappelli R, Conti A, Agnelli G. Definition of major bleeding: Prognostic classification. J Thromb Haemost. 2020 Nov;18(11):2852-2860. doi: 10.1111/jth.15048. Epub 2020 Sep 11. PubMed 32767653 ↗
  • Vanni S, Pelagatti L, Caviglioli C, Fabiani G, Caldi F, Pellegrino A, Ottaviani M, Innocenti F, Nazerian P. TELOS-plus identifies normotensive patients with pulmonary embolism at high risk of 30-day mortality. Int J Cardiol. 2026 Feb 1;444:133974. doi: 10.1016/j.ijcard.2025.133974. Epub 2025 Oct 22. PubMed 41135774 ↗
  • Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available. PubMed 31504429 ↗

Individual participant data

Plan to share: Yes — Pseudonymized individual participant data underlying published results may be shared with qualified researchers for methodologically sound proposals that fall within the scientific scope of the registry and do not overlap with analyses planned by the PERSEUS investigators. Sharing requires approval by the PERSEUS Steering Committee, approval by the competent ethics committee and a data transfer agreement with Azienda Ospedaliero-Universitaria Careggi, in compliance with the GDPR and the Italian Privacy Code.

Supporting information: Study protocol

Time frame: Data will become available beginning 12 months after formal publication of the primary registry outcomes manuscript and will remain accessible for a period of 5 years.

Access criteria: Access requests must be submitted in writing to the Principal Investigator (simone.vanni@unifi.it) and the PERSEUS Steering Committee, including a detailed scientific protocol and statistical analysis plan. Proposals will be evaluated for scientific merit, feasibility, ethical compliance, and non-redundancy by the Steering Committee. Prior to data release, requestors and their home institutions must sign a formal Data Transfer Agreement (DTA) with Azienda Ospedaliero-Universitaria Careggi and obtain appropriate local ethical approval.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2031, 61 months after the start.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 61 months is above that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Jan 2023 → Jun 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jun 19, 2026was Jan 2023
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 1 site removed
Show 8 added (8 Italy)
  • Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro · Bagno a Ripoli, Italy
  • Nuovo Ospedale del Mugello - Azienda USL Toscana Centro · Borgo San Lorenzo, Italy
  • Ospedale San Giuseppe - Azienda USL Toscana Centro · Empoli, Italy
  • Ospedale Santa Maria Nuova - Azienda USL Toscana Centro · Florence, Italy
  • Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro · Florence, Italy
  • Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro · Pescia, Italy
  • Ospedale San Jacopo - Azienda USL Toscana Centro · Pistoia, Italy
  • Ospedale Versilia - Azienda USL Toscana Nord Ovest · Lido di Camaiore, Italy
Show 1 removed
  • Ospedale Versilia - Azienda USL Toscana Nord Ovest · Viareggio, Italy
Oct 7, 2026
Start date
Jan 1, 2023→Jun 19, 2026
Oct 7, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedIn hemodynamically unstable patients (obstructive shock or cardiac arrest) where transport forin whom definitive imaging is unsafe or unfeasiblenot feasible: bedside point-of-care ultrasound (POCUS) / echocardiography demonstrating acuteshowing clear signs of right ventricular overload in combinationtogether with confirmed proximal DVTdeep vein thrombosis, or mobile right heart thromboembolithrombi.
Oct 7, 2026
Interventions
Added Routine clinical care (no study intervention); removed Standard medical treatment. Arms added: Adults with acute pulmonary embolism; arms removed: Adult patients presenting to the ED confirmed diagnosis of acute pulmonary embolism
Oct 7, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedIncidence ofAll-cause mortality at 30-Day All-Cause Mortality daysTime frame: From index pulmonary embolism diagnosis up to 30 days → 30 days after diagnosis
  • ChangedBefore Incidence of 30-Day Pulmonary Embolism (PE)-Related MortalityNow PE-related mortality at 30 daysTime frame: From index pulmonary embolism diagnosis up to 30 days → 30 days after diagnosis
Oct 7, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 7, 2026
  • EditedIncidence of Confirmed Recurrent Venous Thromboembolism (VTE)venous thromboembolismTime frame: From index diagnosis up to 5 years of follow-up → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
  • EditedIncidence of Clinically Relevant Nonrelevant non-Major Bleeding (CRNMB)major bleedingTime frame: From index pulmonary embolism diagnosis up to 30 days → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
  • EditedIncidence of Chronic Thromboembolic Pulmonary Hypertensionthromboembolic pulmonary hypertension (CTEPH) and Post-PE SyndromeTime frame: Assessed during routine follow-up visits at 3 months, 12 months, and annually up to 5 years → From 3 months up to 5 years after diagnosis
  • AddedHemodynamic decompensationTime frame: From diagnosis to hospital discharge or day 30, whichever comes first
  • AddedAll-cause mortality during follow-upTime frame: 3 months, 12 months, and annually up to 5 years after diagnosis
  • AddedPE-related mortality during follow-upTime frame: 3 months, 12 months, and annually up to 5 years after diagnosis
  • AddedMajor bleeding (ISTH criteria)Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
  • AddedPersistent functional limitation after pulmonary embolism (post-PE syndrome)Time frame: 3 months, 12 months, and annually up to 5 years after diagnosis
  • RemovedIncidence of Early In-Hospital Hemodynamic DecompensationTime frame: From hospital presentation up to hospital discharge or maximum 30 days
  • RemovedIncidence of 30-Day Major Bleeding EventsTime frame: From index pulmonary embolism diagnosis up to 30 days
What changed on Oct 15, 2026
  • Time frameChronic thromboembolic pulmonary hypertension (CTEPH)From 3 months up to 5 years after diagnosis → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
  • Time framePersistent functional limitation after pulmonary embolism (post-PE syndrome)3 months, 12 months, and annually up to 5 years after diagnosis → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
  • DescriptionMajor bleeding (ISTH criteria): how it is measured was reworded
across 2 updates, Oct 7, 2026 – Oct 15, 2026
Title
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
Oct 7, 2026
Sponsor
Collaborators added: A.O.U. Città della Salute e della Scienza - Molinette Hospital; collaborators removed: A.O.U. Città della Salute e della Scienza
Oct 7, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Oct 15, 2026
    Secondary outcomes 2 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChronic thromboembolic pulmonary hypertension (CTEPH)From 3 months up to 5 years after diagnosis → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
    • Time framePersistent functional limitation after pulmonary embolism (post-PE syndrome)3 months, 12 months, and annually up to 5 years after diagnosis → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
    • DescriptionMajor bleeding (ISTH criteria): how it is measured was reworded
    + 1 other change: references
  2. Oct 7, 2026
    8 sites added, 1 site removed
    Show 8 added (8 Italy)
    • Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro · Bagno a Ripoli, Italy
    • Nuovo Ospedale del Mugello - Azienda USL Toscana Centro · Borgo San Lorenzo, Italy
    • Ospedale San Giuseppe - Azienda USL Toscana Centro · Empoli, Italy
    • Ospedale Santa Maria Nuova - Azienda USL Toscana Centro · Florence, Italy
    • Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro · Florence, Italy
    • Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro · Pescia, Italy
    • Ospedale San Jacopo - Azienda USL Toscana Centro · Pistoia, Italy
    • Ospedale Versilia - Azienda USL Toscana Nord Ovest · Lido di Camaiore, Italy
    Show 1 removed
    • Ospedale Versilia - Azienda USL Toscana Nord Ovest · Viareggio, Italy
    Start date Jan 1, 2023→Jun 19, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedIn hemodynamically unstable patients (obstructive shock or cardiac arrest) where transport forin whom definitive imaging is unsafe or unfeasiblenot feasible: bedside point-of-care ultrasound (POCUS) / echocardiography demonstrating acuteshowing clear signs of right ventricular overload in combinationtogether with confirmed proximal DVTdeep vein thrombosis, or mobile right heart thromboembolithrombi.
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedIncidence ofAll-cause mortality at 30-Day All-Cause Mortality daysTime frame: From index pulmonary embolism diagnosis up to 30 days → 30 days after diagnosis
    • ChangedBefore Incidence of 30-Day Pulmonary Embolism (PE)-Related MortalityNow PE-related mortality at 30 daysTime frame: From index pulmonary embolism diagnosis up to 30 days → 30 days after diagnosis
    Secondary outcomes 3 edited, 5 added, 2 removed
    What changed in the outcomes
    • EditedIncidence of Confirmed Recurrent Venous Thromboembolism (VTE)venous thromboembolismTime frame: From index diagnosis up to 5 years of follow-up → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
    • EditedIncidence of Clinically Relevant Nonrelevant non-Major Bleeding (CRNMB)major bleedingTime frame: From index pulmonary embolism diagnosis up to 30 days → 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
    • EditedIncidence of Chronic Thromboembolic Pulmonary Hypertensionthromboembolic pulmonary hypertension (CTEPH) and Post-PE SyndromeTime frame: Assessed during routine follow-up visits at 3 months, 12 months, and annually up to 5 years → From 3 months up to 5 years after diagnosis
    • AddedHemodynamic decompensationTime frame: From diagnosis to hospital discharge or day 30, whichever comes first
    • AddedAll-cause mortality during follow-upTime frame: 3 months, 12 months, and annually up to 5 years after diagnosis
    • AddedPE-related mortality during follow-upTime frame: 3 months, 12 months, and annually up to 5 years after diagnosis
    • AddedMajor bleeding (ISTH criteria)Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
    • AddedPersistent functional limitation after pulmonary embolism (post-PE syndrome)Time frame: 3 months, 12 months, and annually up to 5 years after diagnosis
    • RemovedIncidence of Early In-Hospital Hemodynamic DecompensationTime frame: From hospital presentation up to hospital discharge or maximum 30 days
    • RemovedIncidence of 30-Day Major Bleeding EventsTime frame: From index pulmonary embolism diagnosis up to 30 days
    Interventions Added Routine clinical care (no study intervention); removed Standard medical treatment. Arms added: Adults with acute pulmonary embolism; arms removed: Adult patients presenting to the ED confirmed diagnosis of acute pulmonary embolism
    Sponsor Collaborators added: A.O.U. Città della Salute e della Scienza - Molinette Hospital; collaborators removed: A.O.U. Città della Salute e della Scienza
    Title Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
    + 7 other changes: index terms, verification date, description, conditions, design details, data sharing statement and references
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855679
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Collaborators
University of Florence, Azienda USL Toscana Centro, Azienda Ospedaliera di Perugia, Cardarelli Hospital, Naples, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda USL Toscana Nord Ovest, Medical University of Warsaw, Hospital Universitario Ramon y Cajal, A.O.U. Città della Salute e della Scienza - Molinette Hospital
Responsible party
Simone Vanni (Director, High Dependency Unit (OSAI); Associate Professor of Internal and Emergency Medicine, University of Florence, Azienda Ospedaliero-Universitaria Careggi) — Principal investigator
First posted
Oct 2, 2026
Start date
Jun 19, 2026
Primary completion
Jul 2031 (estimated)
Completion
Jul 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Simone Vanni, MD, PhD
Contact
simone.vanni@unifi.it
+393666904459
Matteo Gabriele Monda, MD
Contact
matteogabriele.monda@gmail.com
+393209433394
Simone Vanni, MD, PhD
principal investigator · Azienda Ospedaliero-Universitaria Careggi / University of Florence
Matteo Gabriele Monda, MD
study director · Azienda Ospedaliero-Universitaria Careggi / University of Florence

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion